CJC-1295 (Without DAC)

Introduction

CJC-1295 (without DAC), also known as Modified GRF 1-29, represents a sophisticated synthetic analogue of growth hormone-releasing hormone (GHRH) that has emerged as one of the most extensively studied peptides in growth hormone research and anti-aging investigations. Originally developed by ConjuChem Biotechnologies in the early 2000s, this 29-amino acid peptide was designed to overcome the limitations of natural GHRH, which has a half-life of only 7 minutes due to rapid enzymatic degradation. Through strategic amino acid substitutions at positions 2, 8, 15, and 27, CJC-1295 without DAC achieves remarkable resistance to proteolytic cleavage while maintaining high-affinity binding to growth hormone-releasing hormone receptors (GHRHR) on anterior pituitary somatotroph cells. This molecular engineering has created a powerful research tool that preserves the natural pulsatile growth hormone release patterns essential for physiological function while extending the peptide's biological activity to 30 minutes to 2 hours, compared to mere minutes for endogenous GHRH.

The distinction between CJC-1295 with and without the Drug Affinity Complex (DAC) represents a critical aspect of this peptide's research applications and biological activity profile. CJC-1295 without DAC lacks the maleimidopropionyl-lysine modification that enables covalent binding to endogenous albumin, resulting in a shorter half-life but preservation of natural growth hormone secretion patterns. This characteristic makes it particularly valuable for research investigating physiological growth hormone dynamics, as it stimulates pulsatile GH release that mimics the body's natural circadian and ultradian rhythms rather than providing sustained, non-physiological elevation. Research demonstrates that CJC-1295 without DAC increases growth hormone secretion by 2- to 10-fold for 6+ days following administration, while simultaneously elevating IGF-1 levels by 1.5- to 3-fold for 9-11 days, creating a robust and sustained activation of the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis that underlies many of its investigated biological effects.

The research significance of CJC-1295 without DAC extends across multiple domains of biomedical investigation, from fundamental studies of growth hormone physiology to applied research in aging models, tissue composition analysis, sleep physiology, and metabolic regulation. This peptide functions as a selective GHRH receptor agonist, binding with high affinity to GHRHR and activating the classical G-protein coupled receptor signaling cascade involving cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathways. The resulting increase in growth hormone synthesis and secretion triggers downstream activation of the IGF-1 axis through the JAK-STAT signaling pathway, leading to enhanced protein synthesis, alterations in tissue composition, accelerated tissue repair, and numerous metabolic effects in research models that have positioned CJC-1295 without DAC as a cornerstone compound in growth hormone research. Its ability to provide sustained yet pulsatile growth hormone stimulation while maintaining favorable safety profiles in preclinical investigations makes it an invaluable tool for researchers investigating fundamental questions about growth, aging, metabolism, and the research applications of growth hormone modulation.

GHRH Receptor Signaling and Molecular Mechanisms

The primary mechanism through which CJC-1295 without DAC exerts its biological effects involves high-affinity binding to growth hormone-releasing hormone receptors (GHRHR), members of the class B family of G-protein coupled receptors that are predominantly expressed on somatotroph cells in the anterior pituitary gland. These receptors represent the natural targets for endogenous GHRH and serve as the principal regulatory mechanism for growth hormone synthesis and secretion. CJC-1295 without DAC demonstrates exceptional binding affinity for GHRHR, with the four strategic amino acid modifications significantly enhancing both receptor recognition and resistance to enzymatic degradation. The D-alanine substitution at position 2 prevents aminopeptidase cleavage at the N-terminus, while the glutamine substitution at position 8 enhances receptor binding affinity. The alanine substitution at position 15 provides resistance to endopeptidase cleavage, and the leucine substitution at position 27 improves overall peptide stability, creating a molecule with dramatically extended biological activity compared to natural GHRH.

Upon binding to GHRHR, CJC-1295 without DAC triggers a sophisticated intracellular signaling cascade that begins with conformational changes in the receptor structure, leading to activation of stimulatory G-proteins (Gs) and subsequent stimulation of adenylyl cyclase activity. This enzyme catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), a critical second messenger that serves as the primary intracellular signal for growth hormone gene expression and peptide synthesis. Elevated cAMP levels activate protein kinase A (PKA), which phosphorylates numerous downstream targets including the transcription factor CREB (cAMP response element-binding protein) and other nuclear proteins that regulate growth hormone gene transcription. Research demonstrates that CJC-1295 administration increases total pituitary RNA content and growth hormone mRNA levels while promoting somatotroph cell proliferation, as confirmed through immunohistochemical analysis. These molecular events culminate in enhanced growth hormone synthesis and secretion, with studies showing 70-107% increases in growth hormone release over 12-hour periods following CJC-1295 administration.

The downstream consequences of CJC-1295-stimulated growth hormone release involve activation of the JAK-STAT signaling pathway, a critical mechanism that mediates many of growth hormone's physiological effects throughout the body. Released growth hormone binds to growth hormone receptors on target tissues, causing receptor dimerization and conformational changes that activate associated Janus kinase 2 (JAK2) proteins. Activated JAK2 phosphorylates specific tyrosine residues on the growth hormone receptor, creating docking sites for Signal Transducer and Activator of Transcription 5B (STAT5B) proteins. Phosphorylated STAT5B dimers translocate to the nucleus where they bind to specific DNA sequences and activate transcription of IGF-1, insulin-like growth factor binding protein-3 (IGFBP-3), and acid-labile subunit genes. This transcriptional program results in increased hepatic and peripheral IGF-1 production, with research showing that CJC-1295 administration increases IGF-1 levels by approximately 28% in controlled studies, creating sustained activation of IGF-1-mediated anabolic and metabolic pathways that persist for 9-11 days following treatment.

Growth Hormone Release Patterns and Physiological Integration

One of the most remarkable and research-significant aspects of CJC-1295 without DAC is its ability to preserve and enhance natural growth hormone release patterns while avoiding the potential complications associated with sustained, non-physiological growth hormone elevation. Natural growth hormone secretion follows complex circadian and ultradian rhythms characterized by distinct pulses occurring approximately every 3-4 hours, with the largest pulses typically occurring during deep sleep phases. These pulsatile patterns are essential for optimal physiological function, as continuous growth hormone exposure can lead to receptor desensitization, metabolic disruption, and loss of growth-promoting effects. CJC-1295 without DAC maintains these natural pulsatile patterns by providing transient GHRH receptor stimulation that enhances but does not override the body's endogenous regulatory mechanisms, resulting in increased pulse amplitude and frequency while preserving the fundamental timing and pattern of growth hormone secretion that optimizes biological activity.

Research has demonstrated that CJC-1295 without DAC increases basal (trough) growth hormone levels by 7.5-fold while maintaining normal pulse characteristics, resulting in an overall 46% increase in growth hormone secretion without disrupting circadian rhythmicity. This enhancement of natural patterns is particularly important for sleep-related growth hormone release, as approximately 70% of daily growth hormone secretion occurs during slow-wave sleep phases. Studies show that CJC-1295 administration can enhance deep sleep quality and duration, creating a positive feedback loop where improved sleep supports enhanced growth hormone release, which in turn promotes better sleep quality and recovery. This physiological integration makes CJC-1295 without DAC particularly valuable for research investigating the relationships between sleep, growth hormone, and overall health outcomes, as it can amplify natural processes without creating artificial or potentially harmful hormonal states.

The temporal dynamics of CJC-1295 without DAC action reveal sophisticated pharmacokinetic properties that optimize its research utility while minimizing potential adverse effects. With a half-life of 30 minutes to 2 hours, this peptide provides sustained GHRH receptor activation sufficient to enhance growth hormone secretion patterns over multiple pulse cycles while avoiding the prolonged receptor occupancy that could lead to desensitization or tachyphylaxis. Laboratory studies demonstrate that single doses of CJC-1295 without DAC can influence growth hormone secretion for 2-6 days, with peak effects typically occurring within the first 24-48 hours and gradually declining thereafter. This extended duration of action results from the peptide's resistance to enzymatic degradation rather than prolonged circulation, allowing for less frequent dosing while maintaining physiological growth hormone patterns. The combination of enhanced efficacy and preserved pulsatility makes CJC-1295 without DAC an ideal research tool for investigating long-term growth hormone effects while maintaining the biological relevance of natural secretion patterns.

Body Composition and Metabolic Research Applications

The tissue composition effects of CJC-1295 without DAC in research models represent one of the most extensively studied aspects of its biological activity, reflecting the fundamental role of growth hormone and IGF-1 in regulating lean tissue mass, adipose tissue distribution, and overall metabolic function. Research demonstrates that CJC-1295 administration in animal models produces alterations in tissue composition through multiple interconnected mechanisms involving enhanced protein synthesis, accelerated lipolysis, and modified metabolic regulation. Studies in rodent and primate models show that CJC-1295 administration influences relative lean mass while affecting adipose tissue distribution patterns, with particular alterations in visceral and subcutaneous fat depots in experimental models. These effects appear to result from the coordinated actions of growth hormone and IGF-1 on muscle and adipose tissues, where these hormones promote anabolic processes in skeletal muscle while enhancing catabolic processes in adipose tissue.

The molecular mechanisms underlying CJC-1295's body composition effects involve sophisticated regulation of protein synthesis pathways and lipolytic processes that are mediated through both direct growth hormone actions and IGF-1-dependent mechanisms. In skeletal muscle tissue, IGF-1 activates the PI3K/Akt/mTOR signaling pathway, a critical regulator of protein synthesis and muscle growth that enhances ribosomal protein production, increases amino acid uptake, and promotes muscle fiber hypertrophy. Simultaneously, growth hormone and IGF-1 stimulate lipolysis in adipose tissue through activation of hormone-sensitive lipase and inhibition of acetyl-CoA carboxylase, enzymes that control fat mobilization and utilization. Research shows that these metabolic effects are accompanied by improvements in insulin sensitivity and glucose handling, with CJC-1295 treatment enhancing cellular glucose uptake and reducing insulin resistance markers in experimental models. These coordinated anabolic and metabolic effects contribute to the peptide's potential for improving body composition while supporting overall metabolic health.

Research applications of CJC-1295 in tissue composition studies in animal models provide insights into age-related changes in muscle tissue, metabolic regulation, and adipose tissue dynamics. Laboratory investigations demonstrate that CJC-1295 administration in research models influences lean tissue mass during caloric restriction while affecting adipose tissue metabolism, providing data on tissue composition regulation. The peptide's effects on metabolic rate and energy expenditure in animal models contribute to these observations, with research showing alterations in energy utilization and substrate metabolism patterns in experimental systems. Additionally, CJC-1295's influence on sleep physiology may relate to its tissue effects in research models, as sleep-associated growth hormone release patterns influence metabolic regulation and tissue homeostasis. These multifaceted effects position CJC-1295 without DAC as a valuable research tool for investigating the relationships between growth hormone, metabolism, tissue composition, and aging processes in controlled laboratory settings.

Sleep Optimization and Recovery Enhancement

The relationship between CJC-1295 without DAC and sleep physiology represents a particularly fascinating area of research that highlights the intricate connections between growth hormone regulation, circadian rhythms, and restorative sleep processes. Growth hormone secretion follows a pronounced circadian pattern, with the majority of daily growth hormone release occurring during slow-wave sleep phases, particularly during the first few hours of sleep when delta wave activity is most prominent. CJC-1295 administration in animal models enhances this natural relationship by increasing growth hormone pulse amplitude during sleep while simultaneously influencing sleep architecture. Research indicates that animal models in controlled studies demonstrated alterations in sleep patterns within 1-2 weeks of administration protocols, including modifications in sleep onset latency, sleep consolidation parameters, and sleep-wake cycle characteristics that suggest effects on sleep regulatory mechanisms.

The mechanisms underlying CJC-1295's sleep-enhancing effects likely involve multiple pathways that connect growth hormone signaling with sleep regulatory networks in the brain. Growth hormone and IGF-1 can influence neurotransmitter systems involved in sleep regulation, including GABA-ergic pathways that promote sleep initiation and maintenance, and adenosine systems that regulate sleep pressure and depth. Additionally, the metabolic effects of enhanced growth hormone secretion may contribute to improved sleep quality by optimizing cellular energy metabolism, reducing inflammatory markers, and supporting neuronal recovery processes that are essential for restorative sleep. Research suggests that CJC-1295's ability to enhance deep sleep phases may create a positive feedback loop where better sleep quality supports more robust growth hormone release, which in turn promotes even better sleep architecture and recovery. This bidirectional relationship makes CJC-1295 particularly valuable for research investigating sleep disorders, recovery enhancement, and the role of growth hormone in sleep-dependent physiological processes.

The recovery enhancement properties of CJC-1295 without DAC extend beyond sleep improvements to encompass broader aspects of physiological restoration and adaptation that are mediated through growth hormone and IGF-1 pathways. Enhanced growth hormone secretion supports accelerated tissue repair through increased protein synthesis, collagen formation, and cellular regeneration processes that are essential for recovery from physical stress, exercise, and injury. Research demonstrates that CJC-1295 administration can reduce inflammatory markers and enhance antioxidant defense systems that protect against exercise-induced oxidative damage and cellular stress. The peptide's effects on immune function may also contribute to improved recovery, as growth hormone and IGF-1 support immune cell function and help maintain immunocompetence during periods of physical or psychological stress. These recovery-enhancing properties make CJC-1295 a valuable research tool for investigating optimal recovery strategies, understanding the biological basis of adaptation to stress, and developing approaches to enhance resilience and performance in both athletic and research contexts.

Anti-Aging and Longevity Research

The aging research applications of CJC-1295 without DAC are founded on the well-established decline in growth hormone secretion that occurs with advancing age in mammalian models, a phenomenon known as somatopause that results in progressive reductions in growth hormone and IGF-1 levels across the lifespan. In aged animal models, growth hormone secretion is typically reduced by 50-70% compared to young adult levels, contributing to many of the physiological changes associated with aging including alterations in muscle mass, increased adiposity, reduced bone density, modified immune parameters, and decreased tissue repair capacity. CJC-1295's ability to modulate growth hormone secretion patterns in aged models has positioned it as a key compound in aging research, where it serves as a tool for investigating how growth hormone modulation influences age-associated physiological changes in experimental systems. Research demonstrates that CJC-1295 administration in aged animal models can modulate growth hormone and IGF-1 levels while maintaining physiological pulsatile patterns in research investigations.

The molecular mechanisms underlying CJC-1295's anti-aging effects involve multiple pathways that influence fundamental aging processes at the cellular and systemic levels. Growth hormone and IGF-1 activation of the PI3K/Akt signaling pathway promotes cell survival and resistance to apoptosis while enhancing protein synthesis and cellular repair mechanisms. These hormones also influence telomerase activity and cellular senescence pathways, potentially affecting the rate of cellular aging and the accumulation of senescent cells that contribute to age-related dysfunction. Additionally, growth hormone's effects on immune function, including enhanced T-cell proliferation and natural killer cell activity, may help maintain immunocompetence and reduce the chronic low-grade inflammation (inflammaging) that characterizes aging and contributes to age-related diseases. Research indicates that CJC-1295 administration can improve multiple biomarkers of aging including body composition, bone density, skin thickness, immune function markers, and cognitive performance measures, suggesting broad anti-aging potential that extends across multiple physiological systems.

Longevity research applications of CJC-1295 without DAC encompass both fundamental studies of aging mechanisms and applied research into interventions that may extend healthy lifespan and improve quality of life during aging. The peptide's ability to enhance sleep quality, improve body composition, support immune function, and promote tissue repair addresses many of the key factors that influence successful aging and longevity. Research has shown particular interest in CJC-1295's potential to preserve muscle mass and prevent sarcopenia, as maintaining muscle strength and function is strongly associated with healthspan and independence in older adults. Additionally, the peptide's effects on bone health, cardiovascular function, and cognitive performance make it relevant for research into comprehensive anti-aging interventions that address multiple age-related changes simultaneously. The preservation of natural growth hormone pulsatility with CJC-1295 without DAC is particularly important for longevity applications, as this approach may provide anti-aging benefits while minimizing the potential risks associated with sustained, non-physiological growth hormone exposure that could include insulin resistance, fluid retention, or increased cancer risk in susceptible individuals.

Bone Health and Connective Tissue Research

The effects of CJC-1295 without DAC on bone health and connective tissue integrity represent critical areas of research given the fundamental role of growth hormone and IGF-1 in skeletal development, maintenance, and repair throughout the lifespan. Growth hormone exerts both direct and indirect effects on bone metabolism through actions on osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells), while IGF-1 serves as a primary mediator of growth hormone's anabolic effects on skeletal tissue. Research demonstrates that growth hormone stimulates osteoblast proliferation and differentiation while enhancing collagen synthesis and mineralization processes that are essential for bone formation and strength. Simultaneously, growth hormone and IGF-1 modulate osteoclast activity to promote balanced bone remodeling that maintains skeletal integrity while allowing for adaptation to mechanical stress and repair of microdamage. The age-related decline in growth hormone secretion contributes significantly to bone loss and increased fracture risk in older adults, making CJC-1295's ability to restore growth hormone levels particularly relevant for bone health research.

The molecular mechanisms through which CJC-1295-stimulated growth hormone and IGF-1 influence bone and connective tissue involve complex signaling networks that regulate cellular differentiation, matrix synthesis, and tissue remodeling processes. IGF-1 activates multiple signaling pathways in bone cells including the PI3K/Akt pathway, which promotes osteoblast survival and function, and the MAPK pathway, which enhances collagen and non-collagenous protein synthesis. Growth hormone also stimulates the production of other bone-regulating factors including bone morphogenetic proteins (BMPs) and transforming growth factor-beta (TGF-β) that coordinate bone formation and remodeling processes. In connective tissues throughout the body, growth hormone and IGF-1 enhance the synthesis of collagen, elastin, and proteoglycans that provide structural support and mechanical properties essential for tissue function. Research shows that these effects extend to tendons, ligaments, cartilage, and skin, where enhanced growth hormone signaling can improve tissue strength, elasticity, and repair capacity.

Research applications of CJC-1295 in bone and connective tissue studies have revealed promising potential for addressing age-related skeletal changes, osteoporosis risk, and connective tissue disorders. Laboratory investigations suggest that CJC-1295 treatment may help maintain or improve bone mineral density while enhancing bone quality parameters including trabecular architecture and cortical thickness. The peptide's effects on connective tissue health are of particular interest for research into joint health, as growth hormone and IGF-1 support cartilage maintenance and may help preserve joint function during aging. Additionally, CJC-1295's influence on skin health through enhanced collagen synthesis and cellular repair mechanisms makes it relevant for research into skin aging and wound healing applications. Research indicates that the timing and duration of growth hormone exposure may be critical for optimizing bone and connective tissue benefits, with pulsatile patterns potentially being more effective than continuous exposure for promoting balanced remodeling and avoiding potential adverse effects such as excessive bone turnover or joint swelling.

Metabolic Health and Insulin Sensitivity Research

The metabolic research applications of CJC-1295 without DAC encompass a broad range of physiological processes related to energy homeostasis, glucose regulation, lipid metabolism, and insulin sensitivity that are fundamentally influenced by growth hormone and IGF-1 signaling. Growth hormone demonstrates complex effects on metabolism that can appear paradoxical, as it promotes both anabolic processes (protein synthesis, muscle growth) and catabolic processes (lipolysis, gluconeogenesis) depending on the metabolic state and target tissue involved. In the fed state, growth hormone and IGF-1 primarily exert anabolic effects that promote nutrient uptake and storage, while in the fasted state, growth hormone shifts toward promoting lipolysis and glucose production to maintain energy availability. Research with CJC-1295 has revealed that enhancing physiological growth hormone patterns can improve overall metabolic flexibility and efficiency, allowing for better adaptation to changing nutritional and energy demands while maintaining stable blood glucose levels and insulin sensitivity.

The molecular mechanisms underlying CJC-1295's metabolic effects involve sophisticated regulation of key metabolic pathways and enzyme systems that control glucose and lipid metabolism. In skeletal muscle, IGF-1 activation of the PI3K/Akt pathway enhances glucose transporter (GLUT4) translocation to the cell membrane, improving glucose uptake and utilization while reducing insulin requirements for glucose homeostasis. Growth hormone also influences hepatic glucose production through regulation of gluconeogenic enzymes and glycogen synthesis pathways, helping to maintain stable blood glucose levels during fasting periods. In adipose tissue, growth hormone activates hormone-sensitive lipase while inhibiting acetyl-CoA carboxylase, promoting lipolysis and reducing lipogenesis in a coordinated manner that favors fat oxidation over fat storage. Research demonstrates that these metabolic effects are accompanied by improvements in insulin sensitivity markers including reduced fasting insulin levels, improved glucose tolerance, and enhanced insulin-stimulated glucose disposal rates in peripheral tissues.

Metabolic research with CJC-1295 without DAC has revealed particular promise for addressing age-related metabolic dysfunction, insulin resistance, and metabolic syndrome characteristics that contribute to cardiovascular disease and diabetes risk. Studies suggest that CJC-1295 administration can improve body composition parameters that are strongly associated with metabolic health, including reduced visceral adiposity and increased lean muscle mass that enhance insulin sensitivity and glucose metabolism. The peptide's effects on sleep quality may also contribute to metabolic benefits, as adequate sleep is essential for maintaining insulin sensitivity and glucose homeostasis, while sleep deprivation is associated with increased diabetes risk and metabolic dysfunction. Additionally, research indicates that CJC-1295's influence on inflammatory markers and oxidative stress may help address the chronic low-grade inflammation that contributes to insulin resistance and metabolic disease. These multifaceted metabolic effects position CJC-1295 as a valuable research tool for investigating integrated approaches to metabolic health that address multiple contributing factors simultaneously while maintaining physiological growth hormone patterns that optimize beneficial effects while minimizing potential adverse consequences.

Conclusion

CJC-1295 (without DAC) stands as an exceptional example of rational peptide design and pharmaceutical development, representing a sophisticated molecular tool that has transformed growth hormone research by providing researchers with the ability to enhance and extend natural GHRH signaling while preserving essential physiological pulsatile patterns. Through strategic amino acid modifications that confer enzymatic resistance and enhanced receptor binding, this 29-amino acid synthetic analogue has overcome the limitations of natural GHRH to become one of the most extensively studied and research-relevant peptides in endocrinology and aging research. The compound's unique ability to increase growth hormone secretion by 2- to 10-fold while maintaining natural circadian and ultradian rhythms has enabled groundbreaking research into the fundamental mechanisms of growth hormone physiology, the role of the GH-IGF-1 axis in aging and disease, and the research potential of growth hormone modulation across multiple physiological systems. From its original development at ConjuChem Biotechnologies to its current status as a cornerstone research compound, CJC-1295 without DAC continues to provide invaluable insights into hormone regulation, metabolic health, and the biological basis of aging and longevity.

The comprehensive body of research on CJC-1295 without DAC provides a robust scientific foundation for its continued investigation as a research tool for studying growth hormone physiology, aging mechanisms, and metabolic regulation. Its well-characterized GHRH receptor interactions, documented safety profile in research investigations, and consistent biological activities across multiple experimental systems make it indispensable for researchers exploring fundamental questions about growth, development, metabolism, sleep, and the complex relationships between hormonal signaling and health outcomes. The peptide's ability to enhance body composition, improve sleep quality, support bone health, and optimize metabolic function while preserving natural hormonal patterns offers unique opportunities for advancing research in endocrinology, gerontology, sleep medicine, and metabolic health. As investigational techniques continue to evolve and our understanding of growth hormone biology deepens, CJC-1295 without DAC serves as both a powerful experimental tool and a model system for understanding how peptide modifications can enhance biological activity while maintaining physiological relevance, ensuring its continued importance in biomedical research and its potential for contributing to the development of novel investigational approaches for age-related diseases and metabolic disorders.

References

1. Teichman, S.L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting growth hormone-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism 91(3):799-805. [doi.org]
2. Alba, M. et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in the growth hormone-releasing hormone knockout mouse. American Journal of Physiology-Endocrinology and Metabolism 291(6):E1290-E1294. [doi.org]
3. Ionescu, M. et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism 91(12):4792-4797. [doi.org]
4. Sackmann-Sala, L. et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research 19(6):424-431. [PubMed]
5. Henninge, J. et al. (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis 2(11-12):647-650. [doi.org]
6. Sigalos, J.T. et al. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews 6(1):45-53. [doi.org]
7. Walker, R.F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging 1(4):307-308. [doi.org]
8. Copinschi, G. et al. (2014). Growth hormone secretagogues: history, clinical applications and mechanism of action. Growth Hormone and IGF Research 24(1):1-5. [doi.org]
9. Bowers, C.Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences 54(12):1316-1329. [PubMed]
10. Godfrey, R.J. et al. (2003). The exercise-induced growth hormone response in athletes. Sports Medicine 33(8):599-613. [doi.org]
11. Doessing, S. et al. (2005). Growth hormone and connective tissue in exercise. Scandinavian Journal of Medicine and Science in Sports 15(4):202-210. [PubMed]
12. Veldhuis, J.D. et al. (2005). Endocrine control of body composition in infancy, childhood, and puberty. Endocrine Reviews 26(1):114-146. [doi.org]
13. Boguszewski, C.L. et al. (2017). Mechanisms in endocrinology: clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism. European Journal of Endocrinology 177(6):R309-R321. [PubMed]
14. Giovannini, S. et al. (2008). Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mechanisms of Ageing and Development 129(10):593-601. [PubMed]
15. Clemmons, D.R. (2006). Clinical applications of IGF-1 receptor antagonists. Growth Hormone and IGF Research 16(Suppl A):S55-S59. [doi.org]
16. Bartke, A. (2019). Growth hormone and aging: updated review. World Journal of Men's Health 37(1):19-30. [PubMed]
17. Iranmanesh, A. et al. (1991). Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology and Metabolism 73(5):1081-1088. [doi.org]
18. Corpas, E. et al. (1993). HGH and mammalian aging. Endocrine Reviews 14(1):20-39. [doi.org]
19. Van Cauter, E. et al. (2008). The impact of sleep deprivation on hormones and metabolism. Medscape Neurology 10(1):1-10.